Literature DB >> 19101522

Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.

C Fiévet1, B Staels.   

Abstract

Liver X receptors (LXRs) are nuclear receptors that play a crucial role in regulating the expression of genes involved in lipid metabolism. Ligand activation of LXRs improves cholesterol homeostasis via multiple coordinated effects, and this function is likely to explain in part the protective effects of LXR activation on atherosclerosis reported in animal models. However, LXR activation may also induce undesirable side effects, such as lipogenesis and hypertriglyceridemia. This review discusses the potential to develop LXR modulators as therapeutic agents for atherosclerosis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19101522     DOI： 10.1016/j.bcp.2008.11.026

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  23 in total

1.  Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.

Authors:  Thomas Pfeifer; Marlene Buchebner; Prakash G Chandak; Jay Patankar; Adelheid Kratzer; Sascha Obrowsky; Gerald N Rechberger; Rajendra S Kadam; Uday B Kompella; Gerhard M Kostner; Dagmar Kratky; Sanja Levak-Frank
Journal:  Curr Pharm Biotechnol       Date:  2011-02-01       Impact factor: 2.837

2.  Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.

Authors:  Johannes Schmitt; Bo Kong; Grace L Guo; Andreas Geier; Bruno Stieger; Oliver Tschopp; Simon M Schultze; Monika Rau; Achim Weber; Beat Müllhaupt
Journal:  Liver Int       Date:  2014-02-07       Impact factor: 5.828

3.  Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

Authors:  François Briand; Morgan Tréguier; Agnès André; Didier Grillot; Marc Issandou; Khadija Ouguerram; Thierry Sulpice
Journal:  J Lipid Res       Date:  2009-10-27       Impact factor: 5.922

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

5.  Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux.

Authors:  Andrea J Luthi; Heng Zhang; Dongwoo Kim; David A Giljohann; Chad A Mirkin; C Shad Thaxton
Journal:  ACS Nano       Date:  2011-12-01       Impact factor: 15.881

Review 6.  Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 7.  Biliary cholesterol secretion: more than a simple ABC.

Authors:  Arne Dikkers; Uwe-Jf Tietge
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 8.  Bile acids as regulatory molecules.

Authors:  Phillip B Hylemon; Huiping Zhou; William M Pandak; Shunlin Ren; Gregorio Gil; Paul Dent
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

9.  Alternatives to animal experimentation for hormonal compounds research.

Authors:  M Penza; M Jeremic; C Montani; M Unkila; L Caimi; G Mazzoleni; Diego Di Lorenzo
Journal:  Genes Nutr       Date:  2009-05-26       Impact factor: 5.523

10.  C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis.

Authors:  Shaikh M Rahman; Karalee C Baquero; Mahua Choudhury; Rachel C Janssen; Becky A de la Houssaye; Ming Sun; Shinobu Miyazaki-Anzai; Shu Wang; Naima Moustaid-Moussa; Makoto Miyazaki; Jacob E Friedman
Journal:  Atherosclerosis       Date:  2016-04-01       Impact factor: 5.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.